Stevanato Group, an Italian company that makes glass vials for COVID-19 vaccines, is expected to conduct an initial public offering in the United States. Few details have been made public, but we'll update this page as new information emerges.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Stevanato Group stock price (NYSE: STVN)
Use our graph to track the performance of STVN stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Stevanato Group stock undervalued or overvalued?
Valuing Stevanato Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stevanato Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Stevanato Group's P/E ratio
Stevanato Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Stevanato Group shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Stevanato Group's P/E ratio is best considered in relation to those of others within the medical instruments & supplies industry or those of similar companies.
Stevanato Group's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.5691. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Stevanato Group's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Stevanato Group's PEG ratio in relation to those of similar companies.
Recently Stevanato Group has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Stevanato Group shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Stevanato Group's case, that would currently equate to about $0.054 per share.
While Stevanato Group's payout ratio might seem low, this can signify that Stevanato Group is investing more in its future growth.
Stevanato Group's most recent dividend payout was on 16 July 2025. The latest dividend was paid out to all shareholders who bought their shares by 4 June 2025 (the "ex-dividend date").
Stevanato Group's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Over the last 12 months, Stevanato Group's shares have ranged in value from as little as $17.7607 up to $28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Stevanato Group's is 0.564. This would suggest that Stevanato Group's shares are less volatile than average (for this exchange).
To put Stevanato Group's beta into context you can compare it against those of similar companies.
Stevanato Group S. p. A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices.
Frequently asked questions
What percentage of Stevanato Group is owned by insiders or institutions? Currently 1.658% of Stevanato Group shares are held by insiders and 108.336% by institutions.How many people work for Stevanato Group? Latest data suggests 5,521 work at Stevanato Group.When does the fiscal year end for Stevanato Group? Stevanato Group's fiscal year ends in December.Where is Stevanato Group based? Stevanato Group's address is: Via Molinella 17, Piombino Dese, PD, Italy, 35017What is Stevanato Group's ISIN number? Stevanato Group's international securities identification number is: IT0005452658
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
